Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain

Affiliations

¹ Department of Radiation Oncology, Washington University in St Louis, St Louis, Missouri; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: brian.baumann@wustl.edu.
² Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France.
³ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Editorial

Brian C Baumann et al. Int J Radiat Oncol Biol Phys. 2021.

. 2021 Sep 1;111(1):113-116.

doi: 10.1016/j.ijrobp.2021.04.048.

¹ Department of Radiation Oncology, Washington University in St Louis, St Louis, Missouri; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: brian.baumann@wustl.edu.
² Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France.
³ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, West CML, Lewis R, Hussain SA, James ND, Huddart R, Hoskin P; BC2001 and BCON investigators. Choudhury A, et al. Lancet Oncol. 2021 Feb;22(2):246-255. doi: 10.1016/S1470-2045(20)30607-0. Lancet Oncol. 2021. PMID: 33539743 Free PMC article.

1. Choudhury A, Porta N, Hall E, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: An individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021;22:246–255. - PMC - PubMed
1. Hoskin PJ, Rojas AM, Bentzen SM, et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28:4912–4918. - PubMed
1. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–1488. - PubMed
1. Nagar H, Spratt DE. Challenging the norm: What level of evidence is necessary to adopt postprostatectomy hypofractionated radiation therapy? Int J Radiat Oncol Biol Phys. 2020;107:297–298. - PubMed
1. Fischer-Valuck BW, Roudra S, Gabani P, et al. Impact of facility radiation patient volume on overall survival in patients with muscle invasive bladder cancer undergoing trimodality bladder preservation therapy. Bladder Cancer. 2019;5:235–244.